Global Thyroid Gland Disorder Treatment Market Size
Abbott Laboratories, AbbVie Inc, Allergan Plc, GlaxoSmithKline plc, Lannett Company, Inc, Merck & Co. Inc, Mylan N.V, Novartis AG, Pfizer Inc, and RLC Labs, Inc. among others, are some of the key players operating in the global thyroid gland disorder treatment market
Brooklyn, New York, Feb. 06, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Global Thyroid Gland Disorder Treatment Market is projected to grow at a CAGR of 4.3% from 2023 to 2028.
The rising cases of thyroid disorders, improved healthcare infrastructure and care quality, increase in awareness programs associated with thyroid disorders, and the growing strategic partnerships between pharmaceutical companies and government organizations, are all expected to accelerate the growth of the thyroid gland disorder treatment industry.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC on “Global Thyroid Gland Disorder Treatment Market - Forecast to 2028’’
Key Market Insights
As per the route of administration outlook, the oral segment is expected to be the largest segment in the global thyroid gland disorder treatment market from 2023 to 2028
As per the drug type, the levothyroxine drug segment is expected to be the largest segment in the global thyroid gland disorder treatment market from 2023 to 2028
The Asia Pacific region is analyzed to be the fastest-growing segment in the market
North America will have the largest share of the market during the forecast period
Abbott Laboratories, AbbVie Inc, Allergan Plc, GlaxoSmithKline plc, Lannett Company, Inc, Merck & Co. Inc, Mylan N.V, Novartis AG, Pfizer Inc, and RLC Labs, Inc. among others, are some of the key players operating in the global thyroid gland disorder treatment market
Request for a Sample Copy of the Report @ https://www.globalmarketestimates.com/market-report/thyroid-gland-disorder-treatment-market-3928
Disease Type Outlook (Revenue, USD Billion, 2023-2028)
Hypothyroidism
Hyperthyroidism
Drug Type Outlook (Revenue, USD Billion, 2023-2028)
Levothyroxine
Liothyronine
Propylthiouracil
Imidazole-Based Compounds
Others
Route of Administration Outlook (Revenue, USD Billion, 2023-2028)
Oral
Intravenous Route
Others
Distribution Channel Outlook (Revenue, USD Billion, 2023-2028)
Wholesaler/Distributor
Retailer
Mail-Order Pharmacy
Others
By Regional Outlook (Revenue, USD Billion, 2023-2028)
North America
The U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Thailand
Indonesia
Malaysia
Singapore
Vietnam
Rest of APAC
Central & South America
Brazil
Argentina
Chile
Rest of CSA
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of MEA
Contact: Yash Jain
Director - Global Accounts & Strategic Advisory
Email address: yash.jain@globalmarketestimates.com
Phone Number: +1 6026667238
Website: www.globalmarketestimates.com
CONTACT: Contact: Yash Jain Director - Global Accounts & Strategic Advisory Email address: yash.jain@globalmarketestimates.com Phone Number: +1 6026667238 Website: www.globalmarketestimates.com
